Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1375 of 3499 entries
View as:

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04431024 Org: User:
Start: 03/30/21 End: 06/30/38 Due: 06/30/39

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00267865 Org: User:
Start: 09/14/06 End: 09/19/19 Due: 09/19/20

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Phase: N/A Priority: Normal
NCT ID: NCT01730118 Org: User:
Start: 03/04/13 End: 12/03/19 Due: 12/03/20

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00003934 Org: User:
Start: 06/30/99 End: - Due: -

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00001436 Org: User:
Start: 05/31/95 End: 09/30/00 Due: 09/30/01

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

Phase: N/A Priority: Normal
NCT ID: NCT00001830 Org: User:
Start: 07/20/99 End: 05/19/15 Due: 05/19/16

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00068497 Org: User:
Start: 08/31/03 End: - Due: -

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00310024 Org: User:
Start: 11/30/05 End: - Due: -

Aflibercept for Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00437034 Org: User:
Start: 01/31/07 End: 04/30/11 Due: 04/30/12

Obeticholic Acid for Prevention in Barrett's Esophagus

Phase: N/A Priority: Normal
NCT ID: NCT04939051 Org: User:
Start: 01/03/24 End: 09/29/26 Due: 09/29/27

Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

Phase: N/A Priority: Normal
NCT ID: NCT00923390 Org: User:
Start: 03/02/09 End: 08/24/12 Due: 08/24/13

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03258567 Org: User:
Start: 04/26/18 End: 06/01/31 Due: 06/01/32

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04648826 Org: User:
Start: 12/14/21 End: 12/14/21 Due: 12/14/22

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00253526 Org: User:
Start: - End: - Due: -

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Phase: N/A Priority: Normal
NCT ID: NCT04175912 Org: User:
Start: 03/16/20 End: 10/31/25 Due: 10/31/26

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03592641 Org: User:
Start: 07/25/19 End: 12/30/21 Due: 12/30/22

Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00020410 Org: User:
Start: 02/28/01 End: - Due: -

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01967537 Org: User:
Start: 10/18/13 End: 03/12/18 Due: 03/12/19

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Phase: N/A Priority: Normal
NCT ID: NCT04439240 Org: User:
Start: 05/31/16 End: 06/30/20 Due: 06/30/21

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00295984 Org: User:
Start: 03/31/06 End: 08/31/06 Due: 08/31/07

A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning

Phase: N/A Priority: Normal
NCT ID: NCT00026936 Org: User:
Start: 05/31/99 End: 01/31/05 Due: 01/31/06

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Phase: N/A Priority: Normal
NCT ID: NCT02689453 Org: User:
Start: 01/19/17 End: 06/15/21 Due: 06/15/22

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT00001386 Org: User:
Start: 06/30/94 End: 01/31/02 Due: 01/31/03

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00089362 Org: User:
Start: 07/31/04 End: - Due: -

CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00028028 Org: User:
Start: 02/28/02 End: - Due: -